Clinical Trial Update: 12-week Safety Evaluation of Oral CS-0777 in Multiple Sclerosis Patients [Phase 1]

View source ↗

Summary

This Phase 1 study reports the completion of a 12-week safety evaluation of an oral CS-0777 in patients with multiple sclerosis. It summarizes the safety findin…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Sclerosis

Drugs mentioned

• CS-0777 (CS-0777)

Snippet

Sponsor: Daiichi Sankyo | Conditions: Multiple Sclerosis | Phase 1 | Status: COMPLETED